Venous leg ulcers (VLUs) remain one of the most persistent, costly chronic wounds in payer networks.
Current treatments often fall short and coverage policies overlook promising alternatives. But new clinical evidence may change that.
Join a discussion that explores findings from the most recent randomized controlled trial on amniotic membrane grafts for VLUs and how these insights can not only inform clinical strategy but could directly shape payer policy.
You'll learn:
- How clinical outcomes vary with wound size — and why that matters
- Insights from the newest VLU trial on amniotic membrane efficacy
- What health plans need to evaluate coverage
